BioSpace News Archive

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), today reported financial results for its third quarter ended September 30, 2021 and provided a corporate update.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President, will present at the Evercore ISI 4th Annual HealthconX Conference.

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the 4th Annual Evercore ISI HealthCONx Conference.

Vector Space Biosciences, parent company of Vectorspace AI, announces the following three additions to its Scientific Advisory Board (SAB).

Kata® Clinical app supports Phase Ila proof-of-concept study investigating sterna biologicals’ lead compound SB010 in moderate to severe asthma patients.

Theralase® Technologies Inc. has released the Company’s unaudited 3Q2021 condensed interim consolidated Financial Statements, which provides financial information on the previous fiscal quarter and the quarterly Newsletter which provides an interim clinical data analysis on the Phase II Non-Muscle Invasive Bladder Cancer clinical study.

Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), today announced the filing of its fiscal second-quarter results for the three-month period ending September 30, 2021.

Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, announced that the Board of Directors granted a stock option to purchase 220,000 shares of Zosano’s common stock to a new employee as an inducement award.

TRACON Pharmaceuticals (NASDAQ:TCON), today reported that its partners Alphamab Oncology (stock code: 9966.HK) and 3D Medicines (Beijing) Co., Ltd. announced that envafolimab (KN035), the world’s first single-domain PD-L1 antibody formulated for subcutaneous injection received marketing authorization from the Chinese National Medical Products Administration (NMPA).

Celularity Inc. (Nasdaq: CELU) (“Celularity”), today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the use of CYNK-101 in combination with standard chemotherapy, trastuzumab and pembrolizumab in patients with first-line locally advanced unresectable or metastatic HER2/neu positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.